Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TPN | International Minerals | N-008378 DISCN | 1982-01-01 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
011010 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011013 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011020 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011021 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011054 niacinamide 4% / spironolactone 5% | unapproved drug other | 2020-07-02 |
011218 niacinamide 2% / spironolactone 5% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011220 niacinamide 2% / spironolactone 5% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011312 niacinamide 4% / tazarotene 0.05% | unapproved drug other | 2020-07-02 |
011503 dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2020-07-02 |
011504 dapsone 8.5% / niacinamide 4% | unapproved drug other | 2020-07-02 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyslipidemias | D050171 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | — | — | — | 1 | 2 | — | — | 3 |
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | 2 | — | — | 3 |
Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | — | — | 1 | — | — | 1 |
Hypopharyngeal neoplasms | D007012 | — | C13 | — | — | 1 | — | — | 1 |
Laryngeal diseases | D007818 | — | J38.7 | — | — | 1 | — | — | 1 |
Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Niacinamide |
INN | nicotinamide |
Description | Nicotinamide is a pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor, a metabolite, a cofactor, an antioxidant, a neuroprotective agent, an EC 3.5.1.98 (histone deacetylase) inhibitor, an anti-inflammatory agent, a Sir2 inhibitor, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a mouse metabolite, a human urinary metabolite and a geroprotector. It is a vitamin B3, a pyridinecarboxamide and a pyridine alkaloid. It is functionally related to a nicotinic acid. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1cccnc1 |
PDB | — |
CAS-ID | 98-92-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1140 |
ChEBI ID | 17154 |
PubChem CID | 936 |
DrugBank | DB02701 |
UNII ID | 25X51I8RD4 (ChemIDplus, GSRS) |